why choose us

Course: Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

CME Credits: 1.00

Released: 2021-09-14

COVID-19, which is due to infection with SARS-CoV-2, results in poor outcomes in patients with hematologic cancers (approximately 40% mortality rate)., The efficacy of anti-SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations and also has been reported in immunocompromised patients. Recently, we showed that a first injection of the BNT162b2 (Pfizer-BioNTech) vaccine induced an antibody response in 55% of 112 allogeneic hematopoietic stem cell transplant (HSCT) recipients. Here, we document the antibody response to a second dose of BNT162b2 vaccine in an extended cohort of 117 patients.


Educational Objective
To identify the key insights or developments described in this article


View Full Course